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Exome sequencing of early‑onset 
patients supports genetic 
heterogeneity in colorectal cancer
C. Fernández‑Rozadilla1,14, M. Álvarez‑Barona1,14, I. Quintana2, A. López‑Novo1, J. Amigo3, 
J. M. Cameselle‑Teijeiro4, E. Roman5, D. Gonzalez6, X. Llor7, L. Bujanda8, X. Bessa9, 
R. Jover10, F. Balaguer11, A. Castells11, S. Castellví‑Bel11, G. Capellá12, A. Carracedo13, 
L. Valle12 & Clara Ruiz‑Ponte13*
Colorectal cancer (CRC) is a complex disease that can be caused by a spectrum of genetic variants 
ranging from low to high penetrance changes, that interact with the environment to determine 
which individuals will develop the disease. In this study, we sequenced 20 early‑onset CRC patients to 
discover novel genetic variants that could be linked to the prompt disease development. Eight genes, 
CHAD, CHD1L, ERCC6, IGTB7, PTPN13, SPATA20, TDG and TGS1, were selected and re‑sequenced in 
a further 304 early onset CRC patients to search for rare, high‑impact variants. Although we found a 
recurring truncating variant in the TDG gene shared by two independent patients, the results obtained 
did not help consolidate any of the candidates as promising CRC predisposing genes. However, we 
found that potential risk alleles in our extended list of candidate variants have a tendency to appear at 
higher numbers in younger cases. This supports the idea that CRC onset may be oligogenic in nature 
and may show molecular heterogeneity. Further, larger and robust studies are thus needed to unravel 
the genetics behind early‑onset CRC development, coupled with novel functional analyses and omic 
approaches that may offer complementary insight.
Heritability in colorectal cancer (CRC) is estimated to be between 8 and 40%1,2. However, only 5–10% is explained 
by rare, high-penetrance germline mutations in Mendelian susceptibility genes, such as those in Lynch syn-
drome—caused by pathogenic variants in mismatch repair (MMR) genes, adenomatous polyposis syndromes—
caused by pathogenic variants in APC, MUTYH, NTHL1 or in the exonuclease domain of POLE and POLD13,4.
Except for the identification of RPS20 as a causal gene for hereditary MMR-proficient nonpolyposis CRC, 
the studies undertaken in the past decade to identify new nonpolyposis CRC predisposing genes, have been 
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mostly  unsuccessful5,6. This suggests that the missing CRC heritability is presumably complex and polygenic in 
nature, and is caused by common, low-penetrance risk variants (such as those identified by genome-wide asso-
ciation studies), or by moderately penetrant rarer variants playing an important role in modulating neoplastic 
 transformation7,8.
In this study, we performed whole-exome sequencing (WES) in 20 unrelated patients diagnosed with non-
polyposis CRC at young age. Our purpose was to identify novel rare pathogenic variants that could explain such 
a premature occurrence of the disease.
Results
Patient description and sequencing. Whole-exome sequencing was performed on 20 early-onset CRC 
patients (< = 50  years). Median age at diagnosis was 45  years. All presented with MMR-proficient tumours, 
assessed as the conserved expression of the four MMR proteins MLH1, MSH2, MSH6 and PMS2. The clinical 
features of the patients are described in Supplementary Table 1.
Germline DNA obtained from peripheral blood was sequenced to achieve an average depth of 62.82X, where 
77% of the targeted regions were covered by ≥ 10 reads. This provides a good assessment of inherited variant 
presence. After alignment, calling and annotation, a median of 76,122 variants were identified per individual 
(see Materials and Methods for a detailed description). No pathogenic variants were found in any of the known 
hereditary cancer genes that could account for the observed phenotype.
Variant prioritization. Raw data were analyzed with a prioritization pipeline to reduce the number of 
candidate variants. Briefly, from the initial set of 337,011 unique variants, only those common to both the Life-
Scope™ (Thermo Fisher Scientific, MA, USA) and GATK calling algorithms were  selected9, provided that they 
were found in the same patient and with the same genotype (n = 218,803). Variants annotated as synonymous 
or unknown were removed (n = 187,144), followed by restriction to exonic and splicing changes (n = 34,283). 
Common variants (MAF > 1% and > 0.1% for homozygous and heterozygous calls, respectively) were filtered out 
(n = 6,716 selected rare variants). Protein truncating—frameshift, nonsense -, variants at canonical splice sites, 
and missense changes predicted to have high-functional impact by at least 3 in silico predictors (Dann, Polyphen 
2, CADD) and/or present at highly conserved positions (GERP +  +  ≥ 2), were selected (n = 358)10–13. Lastly, to 
exclude population frequency mismatches, we eliminated any variants found in a Spanish cohort of 267 non-
cancer controls from the MPG cohort of the CIBERER Spanish Variant  Server14. A total of 262 variants in 254 
genes were finally selected after the implementation of this prioritization algorithm (Supplementary Table 2).
Data analysis. Variant and gene‑based analysis. Considering this extended list of 254 candidate genes 
(Supplementary Table 2), there was a median number of 15 variants and 17.5 alleles per patient. We find a ten-
dency for younger patients to have a higher number of rare, high-impact variants. This correlation is both true 
for the number of variants (p = 0.023) and the number of alleles (p = 0.033) (Fig. 1). Eight genes were found to 
have 2 candidate variants each after prioritization, and we found recurring variants, present in at least 3 indi-
viduals, in 11 genes The low presence of variants in recurring genes precluded us from doing gene-burden tests 
from the candidate gene list.
Pathway‑based analysis. We performed pathway-based enrichment analyses based on KEGG pathways (https:// 
www. genome. jp/ kegg/) based on all 262 variants, to test whether there was an overrepresentation of potentially 
damaging rare variants in our cohort based on cancer-related  pathways15. We focused on the following terms: 
Wnt signalling, TGF-β signalling, DNA repair, Pathways in cancer, Apoptosis, Cell adhesion molecules, Colorec-
Figure 1.  Relationship between number of candidate variants/alleles and age. Scatter plots depicting the 
significant trend between number of (A) risk variants (p = 0.021) and (B) risk alleles (p = 0.033) and age in the 
discovery cohort. Figure was created using Stata v11 (StataCorp—www. stata. com).
3
Vol.:(0123456789)
Scientific Reports |        (2021) 11:11135  | https://doi.org/10.1038/s41598-021-90590-z
www.nature.com/scientificreports/
tal cancer, DNA replication, Hippo signalling pathway, MAPK signalling pathway, MicroRNAs in cancer, PI3K-
Akt and PPAR signalling. However, none of the results were statistically significant after performing Fisher´s 
exact tests (Supplementary Table 3). We also performed hypothesis-free Gene Ontology enrichment analyses 
with PANTHER using Reactome pathway descriptions, also with no statistically significant results (Supplemen-
tary Table 4)16. Interestingly however, some of the top hit pathways correspond to known carcinogenetic routes, 
such as TET1 demethylation, ion channel transport or glycogenolysis (as per the Warburg effect)17.
Candidate gene selection. We selected 8 genes for replication in an independent familial/early-onset 
CRC cohort: CHAD, CHD1L, ERCC6, ITGB7, PTPN13, SPATA20, TDG and TGS1 (Table 1)18–21. These were 
selected based on their prior description in early-onset sequencing studies, involvement on cancer-related 
KEGG pathways, presence of the mRNA/protein in healthy colonic mucosa (Protein Atlas, www. prote inatl as. 
org), or variants found in patients under 40 years (Supplementary Table 2).
Candidate gene resequencing. Replication cohort. The replication cohort consisted of 304 non-related, 
MMR-proficient, familial and/or early-onset non-polyposis CRC patients recruited at the Hereditary Cancer 
Program of the Catalan Institute of Oncology, IDIBELL (Catalonia, Spain) (Supplementary Table 5)22.
Mutational screening of CHAD, CHD1L, ERCC6, ITGB7, PTPN13, SPATA20, TDG and TGS1 was performed 
using a combination of PCR amplification in pooled DNAs and targeted massively parallel sequencing (See 
Materials and Methods for detailed description).
Candidate‑gene variants. Prioritization filters were applied to the results of the targeted sequencing of the 8 
genes, in an identical manner to those in the discovery phase. Thirteen variants in 6 of the candidate genes were 
found to fulfil our criteria. All variants were found in heterozygosity. None of the patients in the replication 
phase had more than one rare, high-impact variant in any of these genes (Table 2).
Interestingly, the same variant in TDG (p.(Q23X)) was found in a single patient form the validation cohort 
as well as in the discovery cohort. We hence performed immunohistochemistry (IHC) assays on tumour biopsy 
samples from one of the patients to assess potential second allele inactivation. However, these revealed no dif-
ferences in protein expression between the tumour tissue and the adjacent normal (Supplementary Figure S1).
Next, we compared the results found in our discovery and replication round with those found in the MPG 
Spanish reference cohort (control population)14. Twenty-three rare, high impact variants in 7 of the candidate 
genes were found in this cohort (Supplementary Table 5). Furthermore, we found no evidence for enrichment 
in rare variants in these 7 genes when comparing the cumulative allele count in the CRC patients with those in 
the MPG Spanish population reference dataset (Supplementary Table 6).
In parallel, we also looked into the prevalence of high-impact, rare variants in the eight candidate genes in 
the data published by Chubb and  colleagues19. This included data on 1,006 early-onset familial CRC cases and 
1609 healthy controls. Of the eight candidate genes, only TDG showed enrichment for nonsense, frameshift, 
missense predicted to be damaging and splice donor/acceptor-site variants in early-onset CRC patients compared 
to controls (n 8/1006 cases vs. 4/1609 controls) (Supplementary Table 7).
TCGA germline variants in the candidate genes. TCGA germline samples from colorectal cancer patients (from 
the COAD and READ cohorts; n = 219 Caucasians) were used to search for further evidence of variants in the 
8 replicated genes being relevant to early-onset CRC 23. Variants were assessed in the same way as described for 
the prioritization algorithm in “Variant prioritization” section. We found 21 heterozygous, rare, high-impact 
germline variants in 5 of the 8 replicated genes (Table 3). Seven of these were present in patients that had been 
diagnosed at 50 or earlier. We also observed a shift of variants in the complete list of genes in younger TCGA 
patients, although in this case, it was not statistically significant (p = 0.817) (Supplementary Fig. S2).
Table 1.  Candidate variants in the discovery cohort. Potential risk genes identified in the discovery cohort and 
selected for replication, with their corresponding detected rare, high-impact changes.
Gene Variant description Patient Relevance
CHAD NM_001267:c.1049C > T:p.(T350I) PC-005;PC-015 PI3K-Akt pathway; present in individual with diagnosis before 40y; gene described in early-onset  literature16
CHD1L NM_004284:c.2398delT:p.(L800X) PC-012 Loss-of-function variant; gene described in early-onset  literature17
ERCC6 NM_000124:c.3437_3438insAAG:p.(S1146delinsRS) PC-013 Nucleotide Excision Repair (NER); loss-of-function variant; gene described in early-onset  literature18
ITGB7 NM_000889:c.1063_1066del:p.(V355fs) PC-008 PI3K-Akt pathway; loss-of-function variant; gene described in early-onset  literature16,19
PTPN13 NM_080685:c.4258 + 2 T > C PC-008 Apoptosis; other gene family members have been described as potential candidates for CRC  susceptibility16
SPATA20 NM_022827:c.151C > T:p.(R51X) PC-015 Present in individual with diagnosis before 40y; loss-of-function variant; gene described in early-onset  literature16,19
TDG NM_003211:c.67C > T:p.(Q23X) PC-018 Base Excision Repair (BER); loss-of-function variant; gene described in early-onset  literature17
TGS1 NM_024831:c.439_444del:p.(147_148del) PC-017 Peroxisome Proliferator-activated Receptors (PPAR) pathway; gene described in early-onset  literature17
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Tumour variation profiles were also inspected in the search for a second somatic hit in the TCGA patients 
carrying these mutations (https:// portal. gdc. cancer. gov/). We found an additional somatic missense variant 
(p.(P677L)) in a patient carrying the germline ERCC6 p.(R683Q) change. Because ERCC6 is implicated in DNA 
nucleotide-excision repair (NER) repair, we inspected the mutation signature profile of the tumour with the 
help of the MuSiCa  software24. It showed that signature 3 (associated with homologous recombination) was 
actually the most prevalent, whereas patterns related to NER (albeit not with CRC), such as signatures 4, 7, 11, 
22 and 24, contributed only marginally, which did not support our hypothesis that the ERCC6 mutations were 
the drivers behind the early development of the tumour (Supplementary Table 8) (https:// cancer. sanger. ac. uk/ 
cosmic/ signa tures_ v2. tt).
Interestingly, for the remaining TCGA patients carrying germline changes in these candidate genes, over 
half of these mutation profiles showed a predominant effect of signature 3. This signature has been related to 
Table 2.  Variants found in the eight candidate genes in the replication cohort. Thirteen rare, high-impact 
variants were found in six of the eight genes selected for validation. None of the patients carried more than one 
variant.
Gene Variant description Age at diagnosis
CHAD NM_001267:c.735C > A:p.(Y245X) 37 (patient I-0540-00) & 41 (patient I-2323-03)
CHD1L NM_004284:c.607G > A:p.(G203R) 50
CHD1L NM_004284:c.2273G > A:p.(R758Q) 50
CHD1L NM_004284:c.2320G > A:p.(D774N) 39
CHD1L NM_004284:c.263 T > G:p.(L88W) 45
PTPN13 NM_080685:c.1916G > A:p.(G639E) 49
PTPN13 NM_080685:c.2015A > G:p.(H672R) 50
PTPN13 NM_080685:c.5837G > A:p.(G1946E) 34
SPATA20 NM_022827:c.1177G > A:p.(G393R) 46
SPATA20 NM_022827:c.1426C > T:p.(R476W) 38
TDG NM_003211:c.C67T:p.(Q23X) 49
TDG NM_003211:c.T1175G:p.(I392S) 43
TGS1 NM_024831:c.107G > A:p.(R36Q) 42
Table 3.  Variants in the candidate genes in TCGA CRC samples. Twenty-one variants in five of the candidate 
genes were found in TCGA CRC COAD/READ samples. Seven of these were found in patients under 50 years 
of age (in bold).
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deficient repair processes involving BRCA1 mutations but was not expected directly for a tumour arising from 
the variants in our candidate genes (Supplementary Table 8).
Discussion
In this study, we performed whole-exome sequencing to discover novel rare CRC susceptibility variants that could 
be responsible for the early onset of disease observed in these patients. For this purpose, we selected candidate 
high-impact rare variants obtained from the sequencing of 20 unrelated early-onset CRC patients. Then, we 
selected 8 genes as potential candidates, to be replicated in a validation cohort.
Remarkably, TDG turned out to be the most interesting gene in our analyses. It is a BER gene that has been 
proposed as a tumour suppressor as well as a Wnt pathway regulator and epigenetic modifier in CRC 25–29. In our 
study, a TDG truncating variant p.(Q23X) appeared in two unrelated individuals. Unfortunately, the IHC results 
did not show any differences between normal and tumour protein levels to account for a second somatic event. 
Hence, the results obtained for these 8 genes from our analyses did not provide support enough to claim any of 
them as a strong candidate for CRC  susceptibility19.
The causes for this lack of conclusive results may be several. Firstly, the fact that all patients present with an 
early onset of the disease does not necessarily mean that the underlying genetic cause is  homogeneous4. This is 
supported by the fact that we hardly found recurring variants or genes in our complete list of rare high-impact 
variants. If so, then larger discovery cohorts would be needed to assess this heterogeneity reliably.
Secondly, CRC development is likely due to arise from the interaction of multiple genetic variants plus envi-
ronmental factors (i.e. it is oligogenic in nature)30,31. Interestingly, we found a trend that younger patients have 
a higher proportion of rare, high-impact variants and alleles. Moreover, we do observe that some of the top hits 
in our pathway analyses correspond to known CRC carcinogenetic pathways, including TET1  methylation32,33, 
ion channel  transport34 and colorectal  carcinogenesis35,36. These would support the idea of multiple, moderately 
penetrant variants being responsible for the early-onset phenotype.
Lastly, the vast amount of data produced by sequencing makes it necessary to utilize prioritization algorithms 
that are somewhat arbitrary. The approach chosen for prioritization depends on prior knowledge of the patient 
selection criteria (as described above), the damaging effect of variants encountered in the genes, the inheritance 
model and the function of the genes affected, which is often (if not always)  unavailable37. In this complicated 
scenario, it is then easy to envisage why not only this current study, but also other previous works inspecting the 
genetic contribution to early onset CRC development have been underwhelming. In this sense, other strategies 
may be pursued in order to explore the data more comprehensively. For instance, integration of genetic variation 
with other data sources such as transcriptomic gene expression of methylation levels may be useful in prioritizing 
candidates in a more meaningful  way38.
In any case, it is guaranteed that larger studies are needed. These ought to be appropriately designed and 
powered to detect the expected genetic heterogeneity. In the era of Open Data Science, we must hence walk 
towards making coordinated efforts in order to obtain robust results, particularly for cases that are rare within 
the CRC spectrum, and that are presumably molecularly heterogeneous. Hopefully too, the near future may 
also facilitate data interpretation via complementation with functional data, such as CRISPR assays or in vitro 
organoid models, which would be certainly helpful to increase the throughput in the functional screening of 
candidate genes, and may prove invaluable in validating novel CRC susceptibility loci.
Materials and methods
Study patients: discovery cohort. The study received the approval of the Ethics Committee (CEIC Com‑
ité Ético de Investigación Clínica de Galicia (2011-123). The discovery dataset consisted of 20 non-related and 
unexplained MMR-proficient CRC cases from the EPICOLON  consortium39. All patients received informed 
consent and protocols were at all times in accordance with the tenets of the declaration of Helsinki. The selected 
patients were all diagnosed with CRC before/at the age of 50, with tumours showing microsatellite stability and/
or conserved expression of the MMR proteins (MLH1, MSH2, MSH6, and PMS2). Patients either showed appar-
ently sporadic, autosomal recessive or incomplete-penetrance dominant inheritance patterns. None of these 
patients had detectable germline mutations (point mutations or small indels) in the MMR, MUTYH or BMPR1A 
genes, as assessed by bidirectional Sanger sequencing and Multiplex Ligation-dependent Probe Amplification 
(MLPA) initially, and verified by exome sequencing in this study.
Whole‑exome sequencing (WES). WES was performed on genomic DNA extracted from peripheral 
blood cells of all patients. DNA extraction was undertaken using the CHEMAGEN robot (Chemagen Biopoly-
mer-Technologie AG, Baesweiler, Germany) and the sequencing was performed using the SureSelect Human All 
Exon kit V5 for library preparation (Agilent Technologies, Santa Clara, CA, USA) and ran on a 5500xl SOLiD™ 
system (Thermo Fisher Scientific, Massachusetts, USA). The sequencing reads were aligned to the hg19 reference 
genome using the software provided by the sequencer. Variant calling was performed using both the Lifescope 
and GATK 3.0 suites. For LifeScope, variant QC was performed employing the diBayes parameter of low astrin-
gency level (dibayes.het.min.start.pos = 2 and dibayes.hom.min.nonref.start.pos = 2). Additionally, we removed 
variants with a depth < 30X, variants with a calculated strand bias p value > 0.05, and all alternative allele vari-
ants with < 4 reads to minimise artifacts and select for high quality variants. For GATK, variant QC comprised 
filtering by QUAL >  = 30, a minimum depth per variant of 30 and removal of variants with strand bias p < 0.05. 
An additional filter was applied to exclude variants with < 20% and/or < 4 variant reads, to mimic LifeScope 
stringency filters. Variants were annotated using ANNOVAR (version 2019Apr09).
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Variant prioritization. A prioritization pipeline was applied to reduce the number of variants of interest. 
Firstly, only variants common to both LifeScope and GATK calling were selected, given that they were found in 
the same patient with the same genotype. Later, rare variants  (MAFgnomAD2.1.1_NFE ≤ 0.1% and 1% were chosen for 
heterozygous and homozygous and calls, respectively). High-functional impact changes: loss-of-function (LoF) 
variants resulting in truncated proteins (nonsense, frameshift) and variants at canonical splice sites (+ -1/2) 
were selected, together with high-impact missense variants predicted by at least three in silico tools: PolyPhen-2 
(selected if probably/possibly Damaging—D/P), CADD_phred ≥ 15, Dann ≥ 0.995), and/or located at conserved 
sites (GERP +  +  ≥ 2). Next, variants present in a representative population cohort of 267 control Spanish were 
eliminated to discard population ancestry bias. These belong to exome sequencing data from “non-cancer” 
healthy controls from the CIBERER Spanish Variant Server [ref same as above]. Sequencing artefacts were 
removed by curating using an in-house database of around 1,300 exomes produced with the same technologies. 
Variants in the eight candidate genes were validated by bidirectional Sanger sequencing.
Variant‑based analysis. Frequency deviations between the detected in our cohort and the expected (as per 
gnomAD v2.1.1 counts in non-Finnish Europeans—NFE) were calculated for variants with at least 3 observed 
alleles using chi-squared tests of Fisher’s exact test if allele counts < 5.
Gene and pathway‑based analyses. We selected the following cancer-related KEGG pathways to test 
whether there was an enrichment of potentially damaging rare variants in our cohort: hsa04310 (WNT signal-
ling), hsa04350 (TGF-β signalling), hsa03430 (MisMatch Repair, MMR), hsa03410 (Base-Excision Repair, BER), 
hsa03420 (Nucleotide Excision Repair, NER), hsa03440 (Homologous Recombination, HR), map03450 (Non-
Homologous End Joining, NHEJ, NHJ), hsa03460 (Fanconi Anaemia), hsa05200 (Pathways in cancer), hsa04210 
(Apoptosis), hsa04514 (Cell adhesion molecules), hsa05210 (Colorectal cancer), hsa03030 (DNA replication), 
hsa04390 (Hippo signalling pathway), hsa04010 (MAPK signalling pathway), hsa05206 (MicroRNAs in cancer), 
hsa04151 (PI3K-Akt)], hsa03320 (PPAR signalling). For this, we performed a Fisher’s exact test using  R40. A 
nominal p value of 0.05 was considered significant.
Gene prioritization and candidate‑gene selecion for replication. We prioritized genes that had 
been described in previous works on early-onset CRC patients and/or those belonging to cancer KEGG path-
ways. Amongst those, we selected 8 genes for replication based on their involvement on cancer-related KEGG 
pathways (as described for the pathway analysis), presence of the mRNA/protein in healthy colonic mucosa 
(Protein Atlas, www. prote inatl as. org), genes with variants in patients under 40 years. All candidate variants in 
the 8 selected genes were validated using Sanger sequencing.
Candidate‑gene resequencing. Replication cohort. For the replication, a total of 304 non-related un-
explained MMR-proficient early-onset non-polyposis CRC patients were included. All cases were affected with 
CRC. The mean age at cancer diagnosis was 41.73 (range: 16–50). A detailed description of the series has been 
described in Belhadj et al.22. All patients were of European origin, and were assessed at the Hereditary Cancer 
Program of the Catalan Institute of Oncology (Spain) between 1999 and 2017. The study received the approval 
of the Ethics Committee of the Institut d’Investigació Biomèdica de Bellvitge (IDIBELL) (PR247/15). As for the 
discovery cohort, all patients received informed consent and recruitment complied with the tenets of the decla-
ration of Helsinki.
Candidate gene sequencing. Targeted resequencing of the 8 novel candidate CRC susceptibility genes was per-
formed on genomic DNA extracted from peripheral blood cells extracted using the FlexiGene DNA kit (Qiagen, 
Valencia, CA). Mutational screening was performed using a combination of PCR amplification in pooled DNAs 
and targeted massively parallel  sequencing41. Primers used for amplification were described in the original pub-
lication. DNA pools were obtained adding equimolecular quantities of each sample (# samples/pool: 48-96). The 
resulting pools were used as templates for PCR amplification of each region of interest using the Phusion High-
Fidelity DNA Polymerase (New England Biolabs, Ipswich, MA, USA). PCR products were checked by electro-
phoresis, purified (QIAquick PCR purification Kit, Qiagen, Valencia, CA, USA) and quantified (NanoDropTM, 
Thermo Fisher Scientific, Waltham, MA, USA). Equimolecular amounts of each purified amplicon were pooled, 
ligated and fragmented using a Covaris S2 (Covaris, Inc. MS, USA). DNA libraries and next generation sequenc-
ing (NGS) at high coverage were performed on a HiSeq-2000 (Illumina, San Diego, CA, USA) at Centro Nacional 
de Análisis Genómico (CNAG, Barcelona, Spain). FASTQ files were mapped to the reference genome GRCh37/
hg19 using the Burrows-Wheeler Aligner (BWA-MEM). BAM files were generated using SAMtools. Only the 
bases with base quality ≥ 30 were used for the analysis. Base-level metrics of all positions were extracted using 
Bam-Readcount. The generated data was used to calculate the estimated number of mutated alleles per pool 
(ENMA), which depends on the number of samples included in each DNA pool. All genomic positions were 
annotated with ANNOVAR and common variants present in the Genome Aggregation Database (gnomAD 
v.2.1.1) with a minor allele frequency (MAF) ≥ 1% were filtered out. The median number of reads per base 
obtained for all coding regions and + /− 5 bp flanking regions of the 8 genes analysed was 9421(5–31,562 reads/
base). The selection of the high-impact functional rare variants was performed using a prioritization pipeline 
identical as described above for the discovery cohort.
Variant validation. Variant-specific KASP genotyping assays (LGC Genomics, Hoddesdon, UK) and/or direct 
automated (Sanger) sequencing were used to validate all the variants in the candidate genes. Sequencing was 
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performed at STAB VIDA (Caparica, Portugal) and Macrogen (Amsterdam, the Netherlands) and data was 
analysed with SeqMan Pro (Lasergene 13, DNASTAR, Madison, WI). The primers used for amplification and 
sequencing were the same as the ones used to amplify the pooled DNAs.
TCGA germline variants on candidate genes. TCGA germline variation was inspected for high-impact 
germline variant, as described in “Variant prioritization” section. For this, aligned bam files were obtained with 
permission access from the GDC data portal (https:// portal. gdc. cancer. gov/). Germline variant calling was 
accomplished using VarScan2. This software is one of the callers used to generate somatic variation files, allows 
for the implementation of a germline calling pipeline as well. The results were filtered following the variant 
criteria described in the previous sections for colorectal COAD and READ samples. Additionally, results were 
restricted to samples of reported white ethnicity to account for population mismatches on allele frequencies.
TCGA second hit validation and somatic mutation profiles. VarScan2 annotated somatic vcf files were retrieved 
from the GDC data portal for the patients identified as carrying potential germline variants in the candidate 
genes, and analysed following the same variant selection criteria. Somatic mutation profiles were obtained using 
the MuSiCa software for mutational signatures using COSMIC v2 profiling.
TDG immunohistochemistry. Immunohistochemical assays were carried out using 4-μm-thick paraffin 
sections in an automatic immunostainer (Autostainer Link 48; Agilent, Santa Clara, CA, USA) equipped with 
a 2-step immunohistochemical staining system (EnVision FLEX/HPR; Dako, Glostrup, Denmark) that uses a 
peroxidase-labelled polymer conjugated to the secondary antibody. Before the immunostainer, the samples were 
treated for antigenic retrieval according to the manufacturer’s protocol in the pre-treatment module (PT link, 
Dako; Agilent). Samples were incubated with a primary antibody against TDG (thymine-DNA glycosylase) 
(polyclonal, pH6, dilution: 1:100, 40 min, Sigma Life Science, St Louis, MO, USA). Nonimmune serum samples 
were substituted for the primary antibodies as negative controls. Normal colonic mucosa was used as a positive 
control.
Conclusions
Sequencing of patients with early-onset CRC may be an important tool to discover novel susceptibility variants 
associated with an early-onset of the disease. In our study, we have discovered evidence that this early disease 
development may be the result of multiple and variable rare moderately-penetrant variants, i.e. CRC susceptibil-
ity is oligogenic and heterogeneous. Hence, further larger and appropriately powered studies are necessary in 
order to unveil the genetics behind it. Alternative complementary approaches such as using interrelated omic 
sources and high throughput functional studies may in the near future offer refinement on strategies based only 
on gene prioritization algorithms.
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